Modality
Cell Therapy
MOA
TROP-2 ADC
Target
CDK2
Pathway
NF-κB
CML
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
Mar 2019
→ Aug 2029
Phase 1Current
NCT08468434
184 pts·CML
2019-03→2029-08·Active
184 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-203.4y awayInterim· CML
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Active
Catalysts
Interim
2029-08-20 · 3.4y away
CML
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08468434 | Phase 1 | CML | Active | 184 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 |